Related Experiment Video

Updated: Aug 29, 2025

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

2.9K

COVID-19 and Diabetes: will Novel Drugs for Diabetes Help in COVID-19?

Hayder Mutter Al-Kuraishy1, Ali Ismail Al-Gareeb1, Gomaa Mostafa-Hedeab2,3

  • 1Department of Clinical Pharmacology and Medicine, College of Medicine, AL-Mustansiriyia University, Baghdad, Iraq.

Current Molecular Pharmacology
|September 12, 2022
PubMed

Insights

Diabetes mellitus (DM) and COVID-19 (coronavirus disease 2019) share a dangerous link, with diabetic patients facing higher risks. Further research is needed to determine if anti-diabetic drugs can manage SARS-CoV-2 infection.

Area of Science:

  • * Infectious Diseases
  • * Endocrinology
  • * Public Health

Background:

  • * COVID-19 (coronavirus disease 2019), caused by SARS-CoV-2, has led to millions of deaths globally.
  • * Diabetes mellitus (DM) is a rapidly growing non-communicable disease, affecting 1 in 11 adults, with projections reaching 642 million by 2040.
  • * DM and its complications are associated with increased COVID-19 severity and mortality, potentially due to weakened immune systems and links to cardiovascular disease.

Purpose of the Study:

  • * To explore the intricate relationship between COVID-19 and diabetes mellitus.
  • * To investigate the potential impact of anti-diabetic drugs on SARS-CoV-2 infection management.

Main Methods:

  • * Review of existing research on COVID-19, diabetes mellitus, and their comorbidities.
  • * Analysis of the role of ACE2 receptors in SARS-CoV-2 infection and pancreatic islet cells.
  • * Examination of immune system defects in diabetic individuals and their implications for viral infections.

Main Results:

  • * Diabetic patients exhibit a higher prevalence in severe COVID-19 cases and mortality rates.
  • * SARS-CoV-2 utilizes ACE2 receptors, present in pancreatic islets, suggesting a direct impact on glucose regulation.
  • * Existing research indicates a strong link between COVID-19 and DM, particularly its secondary complications.

Conclusions:

  • * Diabetic patients require heightened precautions to manage blood glucose levels during the COVID-19 pandemic.
  • * The correlation between COVID-19 and fatal outcomes in diabetic individuals may be linked to underlying cardiovascular conditions.
  • * Further evidence is required to ascertain if anti-diabetic medications can effectively manage SARS-CoV-2 infection beyond blood glucose control.
Keywords:
ACE2 receptorCoronavirusantidiabetic drugsdiabeteshyperglycemiasecondary complications

More Related Videos

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-208:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

2.9K
Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.3K

Related Concept Videos

Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
341
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.7K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.0K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
1.2K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
664
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
390